Century Therapeutics (NASDAQ:IPSC – Free Report) had its target price reduced by Chardan Capital from $11.00 to $7.00 in a research note issued to investors on Monday morning,Benzinga reports.

Century Therapeutics (NASDAQ:IPSC – Free Report) had its target price cut by HC Wainwright from $5.00 to $2.00 in a research report report published on Thursday morning,Benzinga reports.